Company Overview

Citius Pharmaceuticals, Inc. is a late-stage biopharmaceutical company focused on developing and commercializing anti-infective and critical care products that address unmet medical needs in hospital and specialty care settings. The company primarily operates within the biopharmaceutical and specialty pharmaceuticals industries, targeting conditions with limited treatment options or where existing therapies are suboptimal.

The company’s core value proposition centers on reformulating, repurposing, or enhancing existing drugs to reduce development risk and accelerate regulatory pathways. Founded in 2007, Citius Pharmaceuticals has evolved from an early-stage development company into a clinical-stage organization with multiple assets in or near late-stage development, including products aimed at infectious diseases, oncology supportive care, and prescription dermatology.

Business Operations

Citius Pharmaceuticals operates through a single reportable operating segment focused on pharmaceutical development, generating no significant commercial revenue as of its most recent public filings. Its business model is centered on advancing product candidates through clinical trials and regulatory approval, followed by commercialization directly or through strategic partners. Key product candidates include Mino-Lok®, an antibiotic lock solution for catheter-related bloodstream infections; I/ONTAK®, a targeted oncology therapy for cutaneous T-cell lymphoma; and Halo-Lido, a topical formulation for hemorrhoids.

Operations are primarily U.S.-based, with clinical trials conducted at domestic and international sites. The company relies on contract research organizations (CROs), third-party manufacturers, and external clinical investigators rather than maintaining large in-house manufacturing or sales infrastructure. Citius Pharmaceuticals holds intellectual property rights related to its formulations and delivery technologies and has entered into licensing agreements to support development and commercialization.

Strategic Position & Investments

Citius Pharmaceuticals’ strategy emphasizes late-stage, de-risked assets with clearer regulatory pathways, particularly products eligible for expedited FDA review processes. The company has invested heavily in advancing Mino-Lok® through Phase 3 trials under a Special Protocol Assessment with the FDA, positioning it as a potential first-in-class therapy. Another strategic milestone includes the acquisition and advancement of I/ONTAK®, which received FDA approval, marking a transition toward commercial-stage operations.

The company has also structured its oncology assets through Citius Oncology, Inc., a majority-owned subsidiary created to house oncology-focused programs and strategic partnerships. Emerging areas of focus include supportive cancer care and hospital-based anti-infective therapies, leveraging regulatory exclusivity, orphan drug designation, and differentiated clinical profiles to compete in niche markets.

Geographic Footprint

Citius Pharmaceuticals is headquartered in Cranford, New Jersey, United States, and primarily operates within North America. Its clinical development activities extend internationally through trial sites in Europe and other regions, depending on study design and regulatory requirements. While the company does not yet maintain a global commercial footprint, its products are intended for use in hospital and specialty care markets worldwide.

The company’s international presence is largely indirect, facilitated through clinical research collaborations, contract manufacturers, and regulatory consultants. Future geographic expansion is expected to depend on commercialization strategies, potential licensing arrangements, and regulatory approvals outside the United States.

Leadership & Governance

Citius Pharmaceuticals is led by a management team with experience in pharmaceuticals, regulatory strategy, and capital markets. The leadership emphasizes a capital-efficient development model, risk mitigation through late-stage assets, and a focus on regulatory execution as key elements of corporate strategy.

Key executives include:

• Leonard Mazur – Chairman of the Board and Chief Executive Officer
• Myron Holubiak – Vice Chairman of the Board
• Shamil Koniev – Chief Financial Officer
• Dr. Myriam Bouchard – Chief Medical Officer
• Brian Lehn – President and Chief Operating Officer

The board and executive team collectively guide strategic planning, clinical development prioritization, and financing activities, with governance practices aligned to U.S. public company standards and oversight requirements.